Arcutis director sells 4,946 shares in plan trade

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock in an open-market transaction at a weighted average price of $24.38 per share.

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock in an open-market transaction at a weighted average price of $24.38 per share. After the sale, she directly holds 27,567 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025.

Insider Trade Summary 10b5-1

Net Seller: 4,946 shares

Net Sell 1 txn

Insider LIN SUE-JEAN

Role Director

Sold 4,946 shs ($121K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,946	$24.3807	$121K

Holdings After Transaction: Common Stock — 27,567 shares (Direct)

Footnotes (2)

1. F1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 4,946 shares Weighted average sale price: $24.3807 per share Post-transaction holdings: 27,567 shares +3 more

6 metrics

Shares sold 4,946 shares Open-market sale on June 15, 2026

Weighted average sale price $24.3807 per share Common stock sale

Post-transaction holdings 27,567 shares Shares directly owned after sale

Sale price range $24.045–$24.62 per share Range of individual trade prices

10b5-1 plan adoption date December 4, 2025 Rule 10b5-1 trading plan start

10b5-1 plan end date February 19, 2027 Scheduled plan termination

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcutis Biotherapeutics (ARQT) disclose for Sue-Jean Lin?

Arcutis Biotherapeutics reported that director Sue-Jean Lin sold 4,946 shares of common stock in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating it was scheduled in advance.

At what price did Sue-Jean Lin sell Arcutis (ARQT) shares in this Form 4?

The weighted average sale price was $24.3807 per Arcutis share, with trades occurring between $24.045 and $24.62. This range reflects multiple individual transactions aggregated into a single reported sale amount on the Form 4 filing.

How many Arcutis (ARQT) shares does Sue-Jean Lin hold after the reported sale?

Following the transaction, Sue-Jean Lin directly holds 27,567 shares of Arcutis common stock. This figure, reported in the Form 4, represents her remaining direct ownership after selling 4,946 shares in the disclosed open-market transaction.

Was the Arcutis (ARQT) insider sale by Sue-Jean Lin part of a Rule 10b5-1 plan?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan adopted on December 4, 2025, with an end date of February 19, 2027. Such plans schedule trades in advance to reduce concerns about trade timing.

What does the weighted average sale price mean in the Arcutis (ARQT) Form 4?

The weighted average sale price of $24.3807 means the 4,946 shares were sold in multiple trades between $24.045 and $24.62. The average reflects all those trades, and detailed breakdowns are available from the reporting person upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 08:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIN SUE-JEAN

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		S(1)		4,946	D	$24.3807(2)	27,567	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)